| 38.83 0.33 (0.86%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 46.01 | 1-year : | 48.12 |
| Resists | First : | 39.4 | Second : | 41.2 |
| Pivot price | 39.07  |
|||
| Supports | First : | 36.47 | Second : | 30.35 |
| MAs | MA(5) : | 38.15 |
MA(20) : | 38.91 |
| MA(100) : | 34.6 |
MA(250) : | 30.03 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 43.5 |
D(3) : | 35.3 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 41.2 | Low : | 15.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RVMD ] has closed above bottom band by 44.3%. Bollinger Bands are 7.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.29 - 39.44 | 39.44 - 39.59 |
| Low: | 38.06 - 38.24 | 38.24 - 38.43 |
| Close: | 38.54 - 38.82 | 38.82 - 39.09 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Sun, 23 Jun 2024
Goldman Sachs Group Inc. Has $30.21 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Thu, 20 Jun 2024
Revolution Medicines CFO Jack Anders sells $70,774 in company stock By Investing.com - Investing.com
Thu, 20 Jun 2024
Revolution Medicines executive sells over $446k in company stock By Investing.com - Investing.com
Thu, 20 Jun 2024
Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD) - Yahoo Finance UK
Thu, 20 Jun 2024
Insider Sale: EVP, Chief Administrative Officer Mital Patel Sells 40000 Shares of RadNet Inc (RDNT) By GuruFocus - Investing.com Canada
Sat, 15 Jun 2024
This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 165 (M) |
| Held by Insiders | 1.6116e+008 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 12,490 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.2204e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -11 % |
| Return on Assets (ttm) | 550.3 % |
| Return on Equity (ttm) | -22.2 % |
| Qtrly Rev. Growth | 4.57e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -24.95 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -449 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.56 |
| Price to Cash Flow | 5.38 |
| Dividend | 0 |
| Forward Dividend | 1.294e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|